Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

27 September 2021: Editorial

Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC)

Dinah V. Parums *

DOI: 10.12659/MSM.934854

Med Sci Monit 2021; 27:e934854

Abstract

ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic has affected the number of completed clinical trials, particularly in oncology. Between 80-85% of all lung cancers are non-small cell lung cancer (NSCLC), and of these, between 2-3% have an EGFR exon 20 insertion, which is associated with increased cell proliferation, metastasis, and a lack of response to chemotherapy and epidermal growth factor receptor (EGFR) inhibitors. Until this year, there were no available targeted therapies for advanced NSCLC with this genetic subtype. However, in May 2021, the US Food and Drug Administration (FDA) granted accelerated approval for amivantamab-vmjw (Rybrevant®), a bispecific monoclonal antibody, targeting activating and resistant EGFR and MET mutations and amplifications. This FDA approval was for adult patients with locally advanced metastatic NSCLC, with disease progression on or following platinum-based chemotherapy. The FDA also approved the Guardant360® companion diagnostic, a next-generation sequencing platform for circulating tumor DNA (ctDNA), which is a liquid biopsy assay. In 2019, Project Orbis was launched by the FDA Oncology Center of Excellence as a global collaborative review program to facilitate rapid global access for patients to innovative cancer therapies. This Editorial aims to highlight how global regulatory initiatives from the FDA have delivered accelerated approval of the first bispecific therapeutic monoclonal antibody, amivantamab-vmjw (Rybrevant®), and a companion diagnostic for patients with advanced NSCLC with an EGFR exon 20 insertion.

Keywords: Editorial, EGFR, monoclonal antibody, targeted therapy, Non-Small Cell Lung Cancer, NSCLC, met

Conclusions

The recent regulatory approval of amivantamab-vmjw (Rybrevant®), an EGFR and MET bispecific monoclonal antibody, and the Guardant360® companion diagnostic, herald a new era in targeted therapy for patients with advanced NSCLC. When the COVID-19 pandemic has delayed clinical trials and regulatory approvals in oncology, recent global initiatives developed by the FDA helped accelerate the approval of amivantamab-vmjw (Rybrevant®) for patients with advanced NSCLC and mutations in the EGFR gene exon 20 insertion. Future expansion of recent FDA programs, such as Project Orbis, to include more countries and review more regulatory applications could help offset the delays in approvals associated with the ongoing COVID-19 pandemic.

References

1. :: Globocan 2020: Lung cancer

2. Inamura K: Lung cancer: Understanding its molecular pathology and the 2015 WHO Classification: Front Oncol, 2017; 7; 193

3. Sequist LV, Bell DW, Lynch TJ, Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer: J Clin Oncol, 2007; 25(5); 587-95

4. Hirsch FR, Varella-Garcia M, Bunn PA: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer: J Clin Oncol, 2006; 24(31); 5034-42

5. Parums DV: Current status of targeted therapy in non-small cell lung cancer: Drugs Today (Barc), 2014; 50(7); 503-25

6. Hofman P, Barlesi F: Companion diagnostic tests for treatment of lung cancer patients: What are the current and future challenges?: Expert Rev Mol Diagn, 2019; 19(5); 429-38

7. Unger JM, Nghiem VT, Hershman DL: Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies with guideline care and new drug indications: JAMA Netw Open, 2019; 2(9); e1910593

8. Waterhouse DM, Harvey RD, Hurley P: Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: Findings from an American Society of Clinical Oncology Survey: JCO Oncol Pract, 2020; 16; 417-21

9. Lim SM, Pyo KH, Soo RA, Cho BC: The promise of bispecific antibodies: Clinical applications and challenges: Cancer Treat Rev, 2021; 99; 102240

10. Park K, Haura EB, Leighl NB: Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study: J Clin Oncol, 2021; [Online ahead of print]

11. Yun J, Lee SH, Kim SY: Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC: Cancer Discov, 2020; 10; 1194-209

12. Neijssen J, Cardoso RMF, Chevalier KM: Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET: J Biol Chem, 2021; 296; 100641

13. Syed YY: Amivantamab: First approval: Drugs, 2021; 81(11); 1349-53

14. Syed YY:: FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer, 2021

15. Leighl NB, Page RD, Raymond VM: Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer: Clin Cancer Res, 2019; 25(15); 4691-700

16. Leighl NB, Page RD, Raymond VM: Prescribing Information: Rybrevant (amivantamab-vmjw) injection, for intravenous use, 2021

17. de Claro RA, Spillman D, Hotaki LT: Project Orbis: Global collaborative review program: Clin Cancer Res, 2020; 26(24); 6412-16

18. Goldberg KB, Blumenthal GM, McKee AE, Pazdur R: The FDA Oncology Center of excellence and precision medicine: Exp Biol Med (Maywood), 2018; 243(3); 308-12

SARS-CoV-2/COVID-19

13 October 2021 : Editorial

Editorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-...

Med Sci Monit In Press; DOI: 10.12659/MSM.935123  

11 October 2021 : Clinical Research

Clinical Features and Temporal Lung Radiographic Changes in 25 Patients Recovering from COVID-19 Pneumonia:...

Med Sci Monit In Press; DOI: 10.12659/MSM.933381  

08 September 2021 : Clinical Research

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

Med Sci Monit In Press; DOI: 10.12659/MSM.932788  

12 October 2021 : Review article

Silent Hypoxemia in Patients with COVID-19 Pneumonia: A Review

Med Sci Monit 2021; 27:e930776

In Press

13 Oct 2021 : Editorial

Editorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-...

Med Sci Monit In Press; DOI: 10.12659/MSM.935123  

13 Oct 2021 : Clinical Research

Endovascular Repair of Thoracic Aorta Injury: 17 Years of Single-Center Experience

Med Sci Monit In Press; DOI: 10.12659/MSM.934479  

11 Oct 2021 : Clinical Research

Challenges for Polish Community Pharmacists in Provision of Services to Immigrants and Non-Polish-Speakers ...

Med Sci Monit In Press; DOI: 10.12659/MSM.933678  

11 Oct 2021 : Clinical Research

Epidemiology of Birth Defects in Eastern China and the Associated Risk Factors

Med Sci Monit In Press; DOI: 10.12659/MSM.933782  

Most Viewed Current Articles

20 Mar 2020 : Clinical Research

Social Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...

DOI :10.12659/MSM.923921

Med Sci Monit 2020; 26:e923921

15 Apr 2020 : Clinical Research

Psychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...

DOI :10.12659/MSM.924171

Med Sci Monit 2020; 26:e924171

05 May 2020 : Review article

An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development

DOI :10.12659/MSM.924700

Med Sci Monit 2020; 26:e924700

26 Apr 2020 : Clinical Research

Comparison of Prevalence and Associated Factors of Anxiety and Depression Among People Affected by versus P...

DOI :10.12659/MSM.924609

Med Sci Monit 2020; 26:e924609

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750